Rigel Pharma (NASDAQ: RIGL) reported Q3 EPS of ($0.12), $0.02 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $21.5 million versus the consensus estimate of $23.56 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.